activated in vivo by low dose gamma irradiation (Ehrhart organ systems, particularly the lung and pancreas. Sevet al., 1997) , but none of these mechanisms seem likely eral of these similarities could be attributed directly to to play a major role in its activation in vivo during normal TSP-1 activation of TGF-␤1 because the phenotype of growth and development. A variety of more physiologithe TGF-␤1 null mice could be pharmacologically reprocal treatments can also activate TGF-␤1, including deduced by treating wild-type animals with a peptide that glycosylation, calpain, cathepsin, or plasmin proteolysis blocked the activation of TGF-␤1 by TSP-1. Moreover, (see Miyazono and Heldin, 1991; Abe et al., 1998) , and a shift toward the normal phenotype occurred in the exposure to reactive oxygen species (Barcellos-Hoff TSP-1 null animals in response to treatment with a pepand Dix, 1996) or to thrombospondin-1 (Schultz-Cherry tide derived from TSP-1 that activated TGF-␤1. and Murphy-Ullrich, 1993). It is not yet clear which, if any, of these mechanisms of activation are utilized in vivo under normal physiological conditions, although Results plasmin has seemed the most likely (Munger et al., 1997) .
Plasmin activates latent TGF-␤1 by cleaving LAP (LyHistological Similarities between TSP-1 Null ons et al ., 1990) . A detailed model of plasmin-dependent and TGF-␤1 Null Animals activation of the large latent complex has been delinSeeking parallels that would suggest a role for TSP-1 eated in vitro to explain in TGF-␤1 activation in vivo, we evaluated the histopaactivation seen in some cultured cells that involves thology of a variety of organ systems in young mouse urokinase plasminogen activator and the mannose-6-pups that were null for TGF-␤1 or for TSP-1 and comphosphate/insulin-like growth factor II receptor. There pared them to one another and to wild-type animals is correlative in vivo evidence for a plasmin-dependent (summarized in Table 1 ). Mouse pups under 2 1/2 weeks activation of TGF-␤1 in the aortic walls of mice (Grainger of age were chosen for these experiments in order to et al., 1994) and for mannose-6-phosphate receptor make direct comparisons of age-matched animals as involvement in TGF-␤1 activation following liver injury TGF-␤1 null pups do not survive beyond about 4 weeks. (Jirtle et al., 1991; Saperstein et al., 1994; De Bleser et As expected, there were significant differences among al., 1996). However, the apparent failure of the plasminothese animals, the most dramatic being the subsequent gen-null animals to replicate the pathology of the TGFearly death of the TGF-␤1 null pups. In contrast, the ␤1-null animals and the recent observation that the TSP-1 null animals, although they also suffer some fetal multisystem pathology that these mice do exhibit can wastage, live on to reproduce (Lawler et al., 1998) . Not be alleviated by removal of fibrinogen (Bugge et al., surprisingly, the autoimmune-based diffuse inflamma-1996) suggest that plasmin can not be responsible for tion and wasting syndrome that accompanies the early the majority of the activation of TGF-␤1 in vivo under demise of the TGF-␤1 null animals was not seen in TSP-1 normal physiological conditions. nulls where inflammation was maintained at a low level Here we consider the possibility that thrombosponin most organs (lung, liver, and pancreas) and was comdin-1 (TSP-1) is an important activator of TGF-␤1 in vivo.
pletely absent from others, such as the heart. Some TSP-1 is a large homotrimeric protein that is secreted histological abnormalities such as the inflammation of by many cell types (see Lahav, 1993; Bornstein, 1995) . the heart were confined to the TGF-␤1 null animals. In cell-free systems, it binds to and activates both small Other defects were specific to the TSP-1 nulls, such as and large latent forms of TGF-␤1 (Murphy-Ullrich et al., the skeletal kyphosis and the excessive vascularity of 1992; Schultz-Cherry et al., 1994a; Souchelnitskiy et al., the pancreatic islets and the dermis. 1995). This plasmin-independent activation is thought Despite these important differences, a careful histoto be the result of a conformational change, possibly logical analysis revealed that the pups of the two null in the LAP  genotypes had markedly similar abnormalities in many Schultz-Cherry et al., 1994a; S. M. F. R. et al., submitted) .
other organs (Table 1) . Some of these, such as the 3-fold It requires the presence of the central type 1 repeats of increase in mitoses seen in the testes and gastric epithethe TSP-1 protein (Schultz-Cherry et al., 1994b) and can lium of both TGF-␤1 and TSP-1 null pups, suggested a be reproduced by small peptides derived from one of parallel loss of TGF-␤1 inhibitory effects in mice of both these repeats that contain amino acids KRFK (Schultzgenotypes. For practical reasons, we have concentrated Cherry et al., 1995) . In activating TGF-␤1, TSP-1 interour more detailed subsequent analyses on two organ acts with the N-terminal region of LAP, forming a trimosystems, the lung and the pancreas. lecular complex. Within the complex, a conformational
In the lung, there were a variety of histopathologic change takes place that alters the immunoreactivity of similarities between the TSP-1 null and the TGF-␤1 null TGF-␤1 (Schultz-Cherry et al., 1995) and makes it accespups. There were vessel abnormalities, as might be exsible to its receptor. Antibodies raised against LAP can pected from the ability of both TGF-␤1 (Majack, 1987 ; block TSP-1 binding (Yang et al., 1997; S. M. F. R. et al., Merwin et al., 1991) and TSP-1 (Majack et al., 1986 ) submitted), and in experiments containing only purified to influence vascular smooth muscle growth. Whereas components, peptides derived from LAP containing the age-matched wild-type mice had thin-walled vessels amino acids LSKL can prevent both TSP-1 binding and ( Figure 1D ) with no evidence of alveolar hemorrhage TGF-␤1 activation (S. M. F. R. et al., submitted).
( Figure 1A ), null animals of both genotypes had bronchiData presented below show that TSP-1 contributes olar arteries that were thickened and tortuous with an significantly to the activation of TGF-␤1 in vivo. A sysincreased number of vascular smooth muscle cell nuclei tematic comparison of the histology of young mouse ( Figures 1E and 1F ). Active TGF-␤s (antibodies recogpups that were null for TSP-1 with pups null for TGF-␤1 disclosed a strikingly similar pathology in multiple nize the active form of TGF-␤s 1, 2, and 3) could be detected in the vascular smooth muscle cell layer of and goblet cells, supporting a metaplastic change. In one third of the TSP-1 null animals, mucinous secretions wild-type animals ( Figure 1G ) but were significantly reduced in TSP-1 null mice ( Figure 1H ). Multifocal capillary were so excessive that the larger bronchi were partially occluded (see mucicarmine stain, Figure 2B ). leakage and alveolar hemorrhage were also common in TSP-1 null ( Figure 1B ) and TGF-␤1 null ( Figure 1C )
These pulmonary changes correlated with the loss of TSP-1 and the lack of TGF-␤ activation. TSP-1 (Figure animals, although they were not seen in wild-type mice ( Figure 1A ). In the TSP-1 null animals, the lung hemor-2E) and active TGF-␤s ( Figure 2H ) were both highly expressed in the wild-type bronchiolar epithelium, and acrhage was seen in areas lacking inflammatory infiltrates and did not directly correlate with the degree of inflamtive TGF-␤s were also seen in underlying tissue. Although the localization of active TGF-␤ may appear mation. Hemorrhage did not resolve with age since hemosiderin-laden macrophages were evident within alvediffuse in these and other photos, evaluation under high power confirmed its extracellular location. TSP-1 was olar spaces in adult mice (Lawler et al., 1998) .
Animals null for either TSP-1 or TGF-␤1 also had simiexpressed well in the TGF-␤1 null pups ( Figure 2G ). In the TSP-1 null animals, although antibodies recognizing lar morphological disturbances in the proximal airway where TGF-␤1 is particularly highly expressed (Jetten all forms of TGF-␤ showed that latent TGF-␤s were clearly present in epithelial cells undergoing proliferative et Zhou et al., 1996) and can induce squamous differentiation and inhibit epithelial cell proliferation (Machanges ( Figure 2F ), the active cytokine was no longer detected in this cell layer ( Figure 2I ). The stain was sui et al., 1986). The proximal segments of the lung of both the TGF-␤1 ( Figures 2C and 2D ) and TSP-1 (Figures clearly working properly as underlying tissue stained well for active TGF-␤s in TSP-1 null animals ( Figure 2I ). 2B, 2F, and 2I) null animals showed hyperplasia, pleomorphism, and increased mitoses, which suggested the Despite the ability of antibodies specific for active TGF-␤s to recognize all three isoforms, tissue from presence of altered proliferation as well as a possible arrest or disturbance in differentiation. These changes TGF-␤1 null animals was negative ( Figure 1J ), suggesting that in this tissue, ␤1 is the dominant active were associated with a shift in the composition of proximal airway cell types to a high number of Clara cells species. The TSP-1 and TGF-␤1 null animals also showed parIn wild-type animals, TGF-␤1 localized to acini ( Figure  3C ) as has been reported for the human pancreas (Yaallel morphological changes in the pancreas, where TGF-␤1 is known to be critical in regulating the balance manaka et al., 1993). The strong staining for active TGF-␤s present in wild-type acini was much reduced in between the acinar and endocrine development (Sanvito et al., 1994) . TSP-1 expression has not previously been acini of TSP-1 null pups ( Figure 3F ). observed in the pancreas, but immunoreactivity of wildtype mice suggested that it is associated with nearly all Peptides Could Restore the Production of Active TGF-␤ in Fibroblasts Cultured from TSP-1 islets and a few interstitial cells ( Figure 3B ) and can be seen in the matrix (evident here in Figure 3H ). ComparaNull Mice and Inhibit Its Production by Wild-Type Fibroblasts ble staining was evident in pediatric human pancreatic tissue (data not shown). All TSP-1 null animals examined If deficiencies in TGF-␤1 activation contribute to the morphological changes observed in the TSP-1 null anihad an increased number of islet cells throughout the organ and exhibited a relative hypoplasia of the exocrine mals, then cells derived from the TSP-1 null animals should be less efficient than those from wild-type anipancreas and interstitial matrix (compare Figure 3A with 3D) that was confirmed by quantitative morphometric mals in activating latent TGF-␤1. As it can be quite difficult to measure levels of active TGF-␤1 in cell secretions analyses ( Table 2 ). The pancreas of TGF-␤1 null animals showed similar but even more striking changes in the (Munger et al., 1997) , to test this prediction we turned to coculturing test cells directly with indicator cells. endocrine and exocrine pancreas with islet cell hyperplasia and moderate to severe inflammation ( Figure 3G) .
Strains of fibroblasts derived from the dermis, where (A-J) Representative sections of bronchial tissue from wild-type animals (A, E, and H), TSP-1 null animals (B, F, and I), and TGF-␤1 null animals (C, D, G, and J) are shown with (B) stained for mucicarmine, (E) and (G) stained for TSP-1, (F) stained for total TGF-␤, and (H), (I), and (J) immunostained specifically for active TGF-␤s. In wild-type tissue, note the single layer of uniform bronchial epithelial cells, which stain positively for both TSP-1 (E) and active TGF␤ (H). In TSP-1 null and TGF-␤1 null animals, bronchial epithelial hyperplasia and focal mucinous metaplasia are evident. In TSP-1 null animals, the metaplastic epithelial cells failed to stain for active TGF-␤s (I), whereas focal positivity is present in bronchiolar smooth muscle cells and infiltrating macrophages. In comparison, antibodies that also recognize latent TGF-␤1 stain this tissue well (F). In TGF-␤1 null animals, TSP-1 staining remained strong (G) and staining for active TGF-␤s was absent (J).
(K-M) Proximal airway bronchial epithelium is shown from a wild-type mouse that was treated with the LSKL peptide that blocked TSP-1 activation of TGF-␤1 (K) and from a TSP-1 null mouse treated with the TSP-1-derived peptide KRFK that activated TGF-␤1 (L and M). (K) and (M) were stained for active TGF-␤s. Similarly stained wild-type tissue is shown in (H). Note changes in the epithelium from a single layer in wild-type animals (A, E, and F) to a metaplastic epithelial lining with enlarged nuclei displaced by goblet-like cells in wild-type animals treated with the blocking peptide (K). Animals lacking TSP-1 that were treated with the activating peptide reverted toward a wild-type bronchial epithelial morphology (L) and showed strong staining for active TGF-␤s (M). All panels, 40ϫ, except (E), 20ϫ.
similar tissue changes were seen in both null animals, in low amounts that were similar to those produced by other cultured cells (Table 3 ; Sato et al., 1990 ; Kojima were isolated from three wild-type pups and three TSP-1 nulls and cocultured for 16 hr with a reporter cell line and Rifkin, 1993; Souchelnitskiy et al., 1995) . The TSP-1 null cells activated only one eighth the amount of TGF-␤ harboring a TGF-␤1-responsive promoter driving the expression of a luciferase reporter gene (Abe et al., 1994) .
that was activated by cells derived from wild-type animals. The deficit in TGF-␤ activation was apparently due Active TGF-␤ was produced by the wild-type fibroblasts to a deficit in TSP-1 because production of active TGF-␤ that pups all gained weight at a similar rate whether treated with KRFK, with a cognate control peptide, could be restored to these cultures by a short peptide derived from TSP-1 (Table 3 ) that has been shown to KQFK, or with PBS. Histological examination revealed that the lungs and the pancreas of all of the KRFKactivate latent TGF-␤1 in biochemically pure systems (Schultz-Cherry et al., 1995) . To verify that the TSP-1 treated pups, but none of the control animals, now had a morphology similar to that of wild-type pups. molecule could activate the latent TGF-␤ produced by TSP-1 null cells, human thrombospondin purified from Each pancreas of animals treated with the activating peptide acquired a more normal phenotype in that their platelets and stripped of bound TGF-␤1 activity was tested. At concentrations from 20 to 80 nM, TSP-1 was islet area decreased relative to acinar area (Table 2; compare Figures 3M and 3N with 3A and 3B). The acini able to activate up to 15% of the total latent TGF-␤ present in this media conditioned by TSP-1 null fibroof the treated pups showed stronger immunoreactivity for active TGF-␤1 ( Figure 3O ) than those from an unblasts in a dose-dependent manner (data not shown).
Fibroblasts cultured from wild-type animals were also treated TSP-1 null pup ( Figure 3F ). The lung and pancreatic tissues of the three pups with control peptide, examined to determine if blocking TSP-1 activation of TGF-␤ would significantly decrease active TGF-␤ pres-KQFK, and of another three pups treated with vehicle PBS were indistinguishable from those of untreated anent in their conditioned media. TSP-1 activates TGF-␤1 by interacting with the latency-associated protein, and imals.
The lungs of the TSP-1 null pups treated with KRFK in purified systems this interaction is prevented by a peptide derived from the latency-associated protein, (Figures 2L and 2M) were morphologically more similar to those of wild-type animals (Figures 2A, 2E , and 2H) LSKL (S. M. F. R. et al., submitted). When this peptide was added to cultured wild-type mouse fibroblasts that than to untreated TSP-1 null animals ( Figures 2B, 2F , and 2I). The epithelial cells of all KRFK-treated pups were secreting TSP-1, the active TGF-␤ that accumulated in their media over a 24 hr period was significantly were less pleomorphic than those of the control peptide-treated animals, and their bronchial epithelium had reduced (Table 4) .
fewer stratified regions and in many areas was a single cell layer thick as it is in wild-type pups. In contrast to Treatment of TSP-1 Null Animals with the TSP-1-Derived Peptide that Activated the bronchial epithelial cells of TSP-1 null animals, which were negative for active TGF-␤ staining ( Figure 2I ), epi-TGF-␤1 Normalized the Pathology of the Pancreas and the Proximal Airway thelial cells of the KRFK-treated TSP-1 null animals stained positively for active TGF-␤s ( Figure 2M ). Overall To link more closely the pathology of the TSP-1 null animals to the ability of TSP-1 to activate TGF-␤1, three the inflammation in the lungs in KRFK-treated animals improved, and aggregates of acute inflammatory cells TSP-1 null mice were treated daily from 3 to 16 days of age with the TSP-1-derived peptide KRFK, which actiwere no longer evident. A mild chronic inflammatory infiltrate did persist in the peribronchial regions of the vates TGF-␤1 in biochemically pure systems (SchultzCherry et al., 1995) and in secretions of TSP-1 null cells lungs, but it was not consistently found in regions of altered epithelial phenotype. (Table 3 ). The treatment caused no apparent toxicity in Dermal fibroblasts were cocultured in the presence or absence of peptides at 50 M with indicator cells containing luciferase under a TGF-␤-sensitive promoter, and luciferase production that was sensitive to TGF-␤-neutralizing antibodies was measured after 16 hr. Standard errors are indicated. 1 different from 2, p Ͻ 0.008; 3 different from 4, p Ͻ 0.03.
Treatment of Wild-Type Animals with a LAP Peptide
active TGF-␤s, prominent in wild-type acinar tissue (Figure 3C ), was reduced in the treated pups ( Figure 3L ).
that Blocks TSP-1 Activation of TGF-␤1 Produced Lung and Pancreatic Phenotypes Similar
The pancreas and the bronchial epithelium of the three pups treated with a control peptide, SLLK, and an addito Those Seen in Null Animals In an experiment parallel to that described above, three tional three treated with vehicle PBS did not differ morphologically or histologically from the untreated animals. wild-type animals were treated with a peptide, LSKL, derived from that portion of the of TGF-␤1 latencyassociated protein (LAP) that interacts with TSP-1 and Discussion curtails TSP-1 activation of TGF-␤1 in pure systems (S. M. F. R. et al., submitted) as well as in complexData presented above demonstrate that TSP-1 is an important natural activator of TGF-␤1 in the lung and in conditioned media (Table 4) . When examined histologically, the proximal airway epithelium of the LSKL-treated the pancreas where both molecules were expressed and where parallel abnormal pathologies were seen in wild-type pups resembled that of the TSP-1 null and TGF-␤1 null pups ( Figure 2K ). It showed focal metaplasia animals null for either one of the two proteins. The histological changes seen in these null mice can be attributed with enlarged nuclei displaced by goblet-like cells, an increased number of Clara cells, and multifocal acute to lack of activation of TGF-␤1 by TSP-1, for they could be reproduced in wild-type pups with a peptide that and chronic inflammatory infiltrates. Staining for active TGF-␤s that was seen clearly in untreated wild-type blocked TSP-1 activation of TGF-␤1 in vitro and reduced the presence of active cytokine in vivo, and they were animals ( Figure 2H ) was lost in the bronchial epithelial cells of treated pups ( Figure 2K ), although areas around ameliorated in TSP-1 null pups by a TSP-1-derived peptide that activated TGF-␤1 in vitro and produced active underlying smooth muscle and macrophages remained positive.
cytokine in vivo. As the peptides were injected IP, it is possible that TGF-␤1 was activated IP and circulated In the pancreas of LSKL-treated animals, qualitative and quantitative increases in the number of islet cells from there to the lung and pancreas, although its short half-life and our ability to stain the active cytokine in were seen ( Figure 3J ; Table 2 ). In all three animals, there was focal dropout of acinar structures ( Figure 3K ), alsitu in peptide-treated animals are more compatible with its being activated locally in individual organs. The simithough it did not approach the degree of hypoplasia or inflammatory-related destruction noted in the pancrelarities between the two null pups extended over multiple organs, suggesting that TGF-␤1 activated by TSP-1 atic tissue of the TGF-␤1 null animals. In 2 of the 3 peptide-treated animals, a mild chronic inflammatory also contributes to the normal development of the testes, bone, kidney, liver, heart, skin, and stomach. TSP-1 infiltrate was found in the pancreas that was composed of predominantly lymphocytes ( Figure 3K ) and was simialso may influence the hematopoeitic systems as both null animals also have increased white blood cell counts lar to that found in both null animals. Reactivity with Serum-free media conditioned for 24 hr in the presence or absence of 1 M peptide by four independently derived wild-type fibroblast cultures were assayed in triplicate for active TGF␤ using the NRK agar colony formation assay. Heat activation of untreated controls resulted in total TGF-␤1 sufficient to induce 191 Ϯ 13 agar colonies/0.5 ml conditioned media. Control of 35 for media plus BSA has been subtracted from all values. Standard error of the mean is indicated. a Different from control peptide, p Ͻ 0.02.
skewed toward monocytes, a smaller thymus, an abnor-TSP-1 in cultured cells derived from vascular smooth muscle and lung epithelium (Penttinen et al., 1988 ; Mamal spleen, and hypercellular bone marrow (data not shown; Shull et al., 1992; Boivin et al., 1995; Lawler et jack et al., 1990; Laiho et al., 1991; RayChaudhury et al., 1994) , both tissues that showed in vivo abnormalities. al., 1998).
Although the antibodies used to stain for active The animal studies presented above suggest several parallels to human disease. In the pancreas, TGF-␤1 is TGF-␤1 recognize all three TGF-␤s, and TSP-1 is able to activate both TGF-␤1 and TGF-␤2 in a manner inhibitknown to stimulate insulin secretion and to block the mitogenic response of pancreatic ␤ cells to glucose able by the inactivating peptide LSKL (S. M. F. R. et al., submitted), most of the abnormalities we observed in (Sjoholm and Hellerstrom, 1991) , raising the possibility that the pancreatic changes seen in the null mice may the TSP-1 null animals and in wild-type animals treated with the inactivating peptide appeared to be specific for represent precursor lesions to insulin-dependent diabetes mellitus or glucose instability. In the lung, the abnor-TGF-␤1, for they were present in the TGF-␤1 null animals and have not been reported in the TGF-␤2 or TGF-␤3 malities seen in both null mice are very reminiscent of the persistent inflammation, mucinous metaplasia, and null mice (Kaartinen et al., 1995; Proetzel et al., 1995; Sanford et al., 1997) , and no active cytokine staining vascular smooth muscle cell hyperplasia that to varying degrees characterize a variety of pulmonary diseases was seen in the lung or pancreas of TGF-␤1 null pups ( Figures 2J and 3I ). It is likely that TSP-1, but not other including asthma and cystic fibrosis. The identification of TSP-1 as a particularly effective activator of TGF-␤1 TSP family members, is activating TGF-␤1. TSP-2 is the family member most similar to TSP-1, but despite one in the lung and the pancreas and the ability of small peptides to modify its effects in vivo suggest new routes report that a preparation enriched for TSP-2 can activate TGF-␤1 (Souchelnitskiy et al., 1995) , TSP-2 lacks the that might be considered to interfere with the progression of such diseases. essential KRFK sequences, and when recombinantly produced, it has no such activity (Schultz-Cherry et al., 1995) .
Experimental Procedures
TSP-1 is the first activator of TGF-␤1 shown to funcAnimals tion in natural, untreated, nondiseased tissues in vivo, TSP-1 null animals (Lawler et al., 1998) and TGF-␤1 null animals yet mice must have additional ways to produce the ac- (Shull et al., 1992) were both generated by homologous recombinative cytokine, for TSP-1 null pups avoid the autoimmune tion in 129/Sv-derived ES cells implanted into C57/BL6 blastocysts destruction and the early death of the TGF-␤1 nulls.
followed by backcrossing with C57/BL6 animals and inbreeding the Even in the lungs of TSP-1 null pups, light focal staining F1. For morphological studies, we examined 9 TSP-1 null animals that were 17 days old and 4 TGF-␤1 null mice aged 10-21 days, for active cytokine was seen, although it was much less both on a mixed C57/Bl6/Sv129 background, 6 TSP-1 null animals intense than in comparable tissue from wild-type anion a Sv129 background, 4 wild-type Sv129 mice, 9 wild-type C57/ mals. Active TGF-␤1 in TSP-1 null mice could be the BL6, and 4 C57/Bl6/Sv129 F1 hybrids within these age brackets.
result of an alternate activation pathway or of the direct Five adult wild-type, TSP-1 null, and TGF-␤1 heterozygous animals release of active cytokine by some cells, as has been and six 1-month-old individuals were also evaluated. Histology was suggested for B cells and plasma cells (Caver et al., consistent among all wild-type animals, and abnormalities seen in null animals were observed in all individuals examined within a single pups begin to fall behind in weight at day 5, the total body weights Acknowledgments of wild-type, TSP-1 null, and peptide-treated animals of the same ages did not differ significantly.
The MLEC used for the TGF-␤ assays were a kind gift of D. B. Rifkin, New York University Medical Center. Technical assistance with hisFor immunohistochemical studies, 5 m sections of formalinfixed, paraffin-embedded tissue sections were placed on poly-Ltology and image processing by Lijun Huang, MD, Yan Mu, MD, Mona Cornwell, and W. Goossens at Children's Memorial Hospital lysine-coated slides, deparaffinized in xylene, rehydrated in descending concentrations of ethanol, washed, and incubated with in Chicago is acknowledged with gratitude as is the preparation of purified human TSP-1 by Olga Volpert. The authors acknowledge specific primary antibodies recognizing TSP-1 (clone A4.1, GIBCO BRL, Gaithersburg, MD), total TGF-␤1 (reactive with both latent and with appreciation NIH grants CA52750 and CA64239 (to N. B.), HL28749 (to J. L.), and HL50061 (to J.E.M.-U.) that supported this active TGF-␤1 from Anogen, Mississauga, Ontario, Canada), or active TGF-␤1,2,3 (clone 1D11.16, cat. #80-1835-03, Genzyme, Cam- work. bridge, MA). The D11.16 antibody neutralizes TGF-␤s 1, 2, and 3 and recognizes active but not inactive TGF-␤1 (and possibly other Received April 13, 1998; revised May 12, 1998 . isoforms) in fixed mouse tissue (Barral-Netto et al., 1992; Caver et al., 1996) . Sections were washed with PBS, incubated with a References biotinylated anti-human IgG (TGF-␤1), anti-mouse IgG (active TGF-␤), or anti-mouse IgM (TSP-1), followed by avidin-biotin peroxiAbe, M., Harpel, J.G., Metz, C.N., Nunes, I., Loskutoff, D.J., and Rifkin, D.B. (1994) . An assay for transforming growth factor-␤ using dase complex (Vectastain kit; Vector Laboratories, Burlingame, CA), and counterstained with hematoxylin. Positive and negative control cells transfected with a plasminogen activator inhibitor-1 promoterluciferase construct. Anal. Biochem. 216, 276-284. slides were run in parallel for TSP-1 and TGF-␤1 staining procedures to verify the specificity of the immunoreactivity. Immunostaining Abe, M., Oda, N., and Sato, Y. (1998) . Cell-associated activation of specificity was also checked by omitting the primary antibody. (1995) . Diversity of function is inherent in matricellular Murine dermal fibroblasts were isolated from 3-to 10-day-old pups proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130, as previously described (Yuspa and Harris, 1974) and used prior to 503-506. passage 6. To collect conditioned media, wild-type fibroblasts were
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